(Q39008917)

English

A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: Efficacy and safety of sodium channel blocker phase II trial.

scientific article published on 11 May 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25960085%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: Efficacy and safety of sodium channel blocker phase II trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25960085%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

phase II clinical trial

0 references

amyotrophic lateral sclerosis

0 references

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25960085%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

Kazumoto Shibuya

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25960085%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Sonoko Misawa

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25960085%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Hideki Kimura

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25960085%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Yu-Ichi Noto

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25960085%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Yasunori Sato

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25960085%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Yukari Sekiguchi

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25960085%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Yuta Iwai

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25960085%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Satsuki Mitsuma

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25960085%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Minako Beppu

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25960085%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Keisuke Watanabe

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25960085%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Yumi Fujimaki

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25960085%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Yukiko Tsuji

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25960085%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Toshio Shimizu

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25960085%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Toshiki Mizuno

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25960085%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Masanori Nakagawa

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25960085%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Kyoko Sawaguchi

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25960085%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Satoshi Kuwabara

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25960085%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

11 May 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25960085%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25960085%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25960085%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

5-6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25960085%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

353-358

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25960085%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Fasciculations, axonal hyperecitability, and motoneuronal death in Amyotrophic Lateral Sclerosis

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2015.1038277

21 January 2018

The origin of muscle fasciculations and cramps

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2015.1038277

21 January 2018

Altered axonal excitability properties in amyotrophic lateral sclerosis: impaired potassium channel function related to disease stage

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2015.1038277

21 January 2018

Axonal excitability properties in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2015.1038277

21 January 2018

Amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2015.1038277

21 January 2018

Dissociated small hand muscle atrophy in amyotrophic lateral sclerosis: frequency, extent, and specificity

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2015.1038277

21 January 2018

Differences in excitability properties of FDI and ADM motor axons.

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2015.1038277

21 January 2018

Split hand syndrome in amyotrophic lateral sclerosis: different excitability changes in the thenar and hypothenar motor axons

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2015.1038277

21 January 2018

Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2015.1038277

21 January 2018

Increased persistent Na(+) current and its effect on excitability in motoneurones cultured from mutant SOD1 mice.

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2015.1038277

21 January 2018

Increased persistent sodium current determines cortical hyperexcitability in a genetic model of amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2015.1038277

21 January 2018

Electrodiagnostic criteria for diagnosis of ALS.

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2015.1038277

21 January 2018

The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2015.1038277

21 January 2018

Rating the severity of ALS by caregivers over the telephone using the ALSFRS-R.

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2015.1038277

21 January 2018

A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2015.1038277

21 January 2018

Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2015.1038277

21 January 2018

Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability.

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2015.1038277

21 January 2018

The effects of mexiletine on excitability properties of human median motor axons

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2015.1038277

21 January 2018

Curcumin abolishes mutant TDP-43 induced excitability in a motoneuron-like cellular model of ALS.

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2015.1038277

21 January 2018

Astrocytes expressing mutant SOD1 and TDP43 trigger motoneuron death that is mediated via sodium channels and nitroxidative stress

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2015.1038277

21 January 2018

Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2015.1038277

21 January 2018

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2015.1038277

21 January 2018

Riluzole, neuroprotection and amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2015.1038277

21 January 2018

Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2015.1038277

21 January 2018

Mexiletine: pharmacology and therapeutic use.

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2015.1038277

21 January 2018

Markedly reduced axonal potassium channel expression in human sporadic amyotrophic lateral sclerosis: An immunohistochemical study

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2015.1038277

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39008917&oldid=1624761123"